%0 Journal Article
%T Pneumococcal vaccination for HIV
%A Eng Lee Tan
%A Oon Tek Ng
%A Paul V Licciardi
%A Peng Li
%J Proceedings of Singapore Healthcare
%@ 2059-2329
%D 2019
%R 10.1177/2010105818773773
%X Susceptibility to infections with pneumococcal bacteria (Streptococcus pneumoniae) is substantially higher among human immunodeficiency virus (HIV)-infected individuals, and accounts for a significant burden of morbidity and healthcare costs. Pneumococcal vaccination is recommended in most countries for HIV-infected adults. Current policy in Singapore and Australia recommends the use of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) as a booster dose following the use of 13-valent pneumococcal conjugate vaccine (PCV13). Despite this, adherence to this policy has been suboptimal in Singapore. This may be related to the fact that PPSV23 has not been shown to have any impact on pneumococcal carriage (the necessary prerequisite for disease development). PPSV23 has also been associated with immune hyporesponsiveness, raising concerns over the use of this vaccine globally and, in particular, in high-risk populations. The lack of data from studies comparing PCV13 and PPSV23 has also contributed to the suboptimal uptake of pneumococcal vaccines by healthcare professionals for HIV-infected individuals. This review article discusses the key issues and importance of rigorous pneumococcal vaccination programmes for HIV-infected individuals. Current recommendations for pneumococcal vaccination of HIV-infected individuals in Singapore should be adopted more readily to reduce the burden of pneumococcal disease in this high-risk group
%K Pneumococcal
%K HIV-infection
%K vaccine
%K adult
%U https://journals.sagepub.com/doi/full/10.1177/2010105818773773